Study looks at policy options to contain high prescription drug costs

AHA News Now

According to a study published today in the Journal of the American Medical Association, the most realistic short-term strategies to address high U.S. prescription drug prices include enforcing more stringent requirements for the award and extension of exclusivity rights; enhancing competition by ensuring... read more

Topic: Advocacy and Public Policy
Tag: drug prices

CMS: Part D drug costs up 17% in 2014

AHA News Now

Prescription drug claims for the 38 million beneficiaries in Medicare Advantage and stand-alone prescription drug plans rose by 3.3% in 2014, while drug costs for the program rose by 17% to $121 billion, according to data released today by the Centers for Medicare & Medicaid Services. Total annual costs... read more

Topic: Advocacy and Public Policy
Tag: drug prices

Coalition briefs Congress on proposals to rein in soaring drug prices

AHA News Now

The Campaign for Sustainable Rx Pricing yesterday held a Capitol Hill briefing and panel discussion on market-based solutions to the nation’s soaring prescription drug prices. “This is a public health crisis….with the health of real patients at stake,” said John Lewin, director of the critical care and... read more

Topic: Advocacy and Public Policy
Tag: drug prices

Senate Judiciary Committee holds hearing on CREATES Act

AHA News Now

The Senate Judiciary Committee today held a hearing on the Creating and Restoring Equal Access to Equivalent Samples Act, AHA-supported legislation that targets anticompetitive behaviors used to block and delay entry of generic drugs. The bipartisan legislation would allow a generic drug manufacturer... read more

Topic: Advocacy and Public Policy
Tags: advocacy, drug prices

AHA voices support for CREATES Act

AHA News Now

The AHA yesterday expressed support for the Creating and Restoring Equal Access to Equivalent Samples Act, which targets anticompetitive behaviors used to block and delay entry of generic drugs. The bipartisan legislation would allow a generic drug manufacturer facing one of these delay tactics to bring... read more

Topic: Advocacy and Public Policy
Tag: drug prices

AHA urges FDA to expand proposed study of consumer drug advertising

AHA News Now

The AHA today urged the Food and Drug Administration to expand its proposed study of direct-to-consumer prescription drug advertising to include televised and internet advertising and to test the impact of other product information on consumer behavior, such as price and comparative effectiveness data.... read more

Topic: Advocacy and Public Policy
Tags: regulation, drug prices

Hospitals, not pharmaceutical manufacturers, are preserving and protecting the safety net

Blog

A group financed by the pharmaceutical industry is hosting a meeting today on the 340B Drug Pricing Program with the goal of “Preserving the True Safety Net.” But what the meeting really will be about is the pharmaceutical industry – with their skyrocketing prescription drug prices and huge profits –... read more

Topic: Access and Coverage
Tags: 340B, Drug Pricing Program, Community benefit, access, drug prices

AHASTAT: Valeant needs to keep its promises

AHA News Now

An article yesterday in the New York Times highlights the yet-to-be-fulfilled promises made by Valeant Pharmaceuticals International to the U.S. Congress, AHA President and CEO Rick Pollack writes in an AHASTAT blog post today. “Valeant had said it would give hospitals discounts of as much as 30% on two... read more

Topic: Advocacy and Public Policy
Tag: drug prices

Valeant Needs to Keep Its Promises

Blog

A recent article in the New York Times highlights the yet-to-be-fulfilled promises made by Valeant Pharmaceuticals International to the U.S. Congress. Valeant had said it would give hospitals discounts of as much as 30 percent on two of its expensive heart drugs. But those discounts never materialized and... read more

Topic: Advocacy and Public Policy
Tag: drug prices

AHA urges CMS to narrow scope of Part B Drug Payment Model

AHA News Now

The Centers for Medicare & Medicaid Services’ proposed payment model for Medicare Part B drugs should not include hospitals, which “have little control over which drugs physicians prescribe in hospital-based settings,” AHA said in comments submitted today. “Even if hospitals could influence physicians’... read more

Topic: Advocacy and Public Policy
Tags: Medicare, regulation, drug prices

Keyword Search

Date